top of page
  • Active, not recruiting

NCT00572169: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy.

Updated: Apr 25, 2022

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy. With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."


total therapy myeloma

Locations

United States, Arkansas

University of Arkansas for Medical Sciences/Myeloma Institute


ClinicalTrials.gov Identifier: NCT00572169

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy - A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance

First Posted : December 12, 2007


clinicaltrials.gov/ct2/show/NCT00572169


 

VDTPACE =

Velcade - Brtezomib

Thalidomide

Dexamethasone

Cisplatin

Adriamycin

Cyclophosphamide